The muddle of models: What you don't know can hurt you

Chemical Research in Toxicology

Volumn 21, Issue 10, 2008, Pages 1917-1922

  Robertson, Donald G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GUANADINO PROPIONIC ACID; BIOLOGICAL MARKER; CERIVASTATIN; COLLAGENASE 3; PHLORETIN; PHLORIZIN; PROPIONIC ACID; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DIABETES MELLITUS; DRUG INDUSTRY; EXPERIMENTAL ANIMAL; KNEE OSTEOARTHRITIS; METABOLIC SYNDROME X; METHODOLOGY; MYOPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBESITY; REVIEW;

ANIMALS; BIOTECHNOLOGY; CREATINE KINASE; DIET; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, ANIMAL; MODELS, BIOLOGICAL;

ANIMALIA;

EID: 55949120449     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800204g     Document Type: Review

References (26)

1. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., and Heller, A. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67.
2. Olson, H., Betton, G., Stritar, J., and Robinson, D. (1998) The predictivity of the toxicity of pharmaceuticals in humans from animal data-an interim assessment. Toxicol. Lett. 102-103, 535-538.
3. Knight, A. (2007) Systematic reviews of animal experiments demonstrate poor human clinical and lexicological utility. Altern. Lab. Anim. 35, 641-659.
4. Peters, T. S. (2005) Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol. Pathol. 33, 146-154.
5. Kola, I., and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. 3, 711-715.
6. Robertson, D. G. (2005) Metabonomics in toxicology: A review. Toxicol. Sci. 85, 809-822.
7. Johnson, A. R., Pavlovsky, A. G., Ortwine, D. R, Prior, F., Man, C. F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., Baragi, V., Lesch, C., Roark, W. H., Wilson, M., Datta, K., Guzman, R., Han, H. K., and Dyer, R. D. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J. Biol. Chem. 282, 27781-27791.
8. Skjevrak, I., Solheim, E., and Scheline, R. R. (1986) Dihydrochalcone metabolism in the rat: trihydroxylated derivatives related to phloretin. Xenobiotica 16, 35-45.
9. Crespy, V., Aprikian, O., Morand, C., Besson, C., Manach, C., Demigne, C., and Remesy, C. (2001) Bioavailability of phloretin and phloridzin in rats. J. Nutr. 131, 3227-3230.
10. Starke, A., Grundy, S., McGarry, J. D., and Unger, R. H. (1985) Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: Implications for human diabetes. Proc. Natl. Acad. Sci. U.S.A. 82, 1544-1546.
11. Zhao, H., Yakar, S., Gavrilova, O., Sun, H., Zhang, Y., Kim, H., Setser, J., Jou, W., and LeRoith, D. (2004) Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53, 2901-2909.
12. Robosky, L. C., Wells, D. F., Egnash, L. A., Manning, M. L., Reily, M. D., and Robertson, D. G. (2005) Metabonomic identification of two distinct phenotypes in Sprague-Dawley (GtCD(SD)) rats. Toxicol. Sci. 87, 277-284.
13. Robosky, L. C., Wells, D. F., Egnash, L. A., Manning, M. L., Reily, M. D., and Robertson, D. G. (2006) Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci. 91, 309.
14. Rohde, C. M., Wells, D. F., Robosky, L. C., Manning, M. L., Clifford, C. B., Reily, M. D., and Robertson, D. G. (2007) Metabonomic evaluation of Schaedler altered microflora rats. Chem. Res. Toxicol. 20, 1388-1392.
15. Boelsterli, U. A. (2003) Animal models of human disease in drug safety assessment. J. Toxicol. Sci. 28, 109-121.
16. Dixit, R., and Boelsterli, U. A. (2007) Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discovery Today 12, 336-342.
17. Wells, D. F., Rohde, C. M., Egnash, L. A., Robosky, L. C., Manning, M. L., Roys, M. D., Reily, M. D., and Robertson, D. G. (2007) Muscle creatine depletion exacerbates cerivastatin-mediated toxicity. Toxicol. Sci. 96, 53-54.
18. Reeves, P. G. (1997) Components of the AIN-93 diets as improvements in the AIN-76A diet. J. Nutr. 127, 838S-841S.
19. Rohde, C. M., Wells, D. F., Robosky, L. C., Egnash, L. A., Manning, M. L., Roys, M. D., Reily, M. D., and Robertson, D. G. (2007) AIN-93G diet eaxacerbates cerivastatin-mediated myotoxicity. Toxicol. Sci. 96, 54.
20. de Wit, N. J., Bosch-Vermeulen, H., de Groot, P. J., Hooiveld, G. J., Grootte Bromhaar, M. M., Jansen, J., Muller, M., and van der Meer, R. (2008) The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. BMC Med. Genomics 1, 14.
21. Cheng, Q., Aleksunes, L. M., Manautou, J. E., Cherrington, N. J., Scheffer, G. L., Yamasaki, H., and Slitt, A. L. (2008) Drugmetabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol. Pharm. 5, 77-91.
22. Schapiro, S. A., and Everitt, J. I. (2006) Preparation of animals for use in the laboratory: Issues and challenges for the Institutional Animal Care and Use Committee (IACUC). ILAR J./Natl. Res. Counc., Inst. Lab. Anim. Resour. 47, 370-375.
23. Conour, L. A., Murray, K. A., and Brown, M. J. (2006) Preparation of animals for research-issues to consider for rodents and rabbits. ILAR J./Natl. Res. Counc., Inst. Lab. Anim. Resour. 47, 283-293.
24. Robertson, D., Beushausen, S., and Pennie, W. (2008) Toxicopanomics: Applications of genomics, proteomics, and metabonomics in predictive and mechanistic toxicology. In Principles and Methods of Toxicology (Hayes, A. W., Ed.) pp 293-324, CRC Press, Boca Raton.
25. Stokes, W. S. (2004) Selecting appropriate animal models and experimental designs for endocrine disrupter research and testing studies. ILAR J./Natl. Res. Counc., Inst. Lab. Anim. Resour. 45, 387-393.
26. Sistare, F. D., and DeGeorge, J. J. (2007) Preclinical predictors of clinical safety: Opportunities for improvement. Clin. Pharmacol. Ther. 82, 210-214.